Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Vectura and UCB to Collaborate and Share Expertise in Severe Inflammatory

Published: Tuesday, October 01, 2013
Last Updated: Tuesday, October 01, 2013
Bookmark and Share
Collaboration for the development of an innovative biologic immunomodulatory product in the area of severe inflammatory.

      UCB and Vectura Group plc have announced that they have entered into a collaboration for the development of an innovative biologic immunomodulatory product in the area of severe inflammatory respiratory disease.

The collaboration aims to leverage Vectura’s expertise in the pharmaceutical and clinical/regulatory development of inhaled therapeutics with UCB’s biologics and immunology assets.

The collaboration will focus on bringing to clinical proof-of-concept a UCB-generated biological therapy targeting a key molecule in the immune system.

The companies will jointly manage the programme, with UCB focusing on bioprocess and preclinical development and Vectura taking responsibility for the pharmaceutical and clinical development of the dry powder product through to clinical proof-of-concept.

Financial terms of the collaboration have not been disclosed.

Dr Mark Bodmer, Vice President UCB New Medicines, Head of Immunology said: “There is significant unmet need that is driven by disorders of the immune system. By bringing together UCB’s biologics and immunology expertise and Vectura’s disease know-how and technologies, we hope to bring relief to people suffering from these severe illnesses worldwide. We are very pleased to be working with Vectura for the unique opportunity created by combining our expertise.”

Dr Chris Blackwell, Chief Executive of Vectura commented: “Vectura’s growth depends in large part on its ability to remain at the cutting edge of development of products targeting airways-related disease. This is a significant collaboration that combines the innovative and development strengths of Vectura and UCB, and mitigates the cost and risk of development of novel products, in line with our stated strategy.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

UCB and Sanofi Partner for Innovation in Immune-Mediated Diseases
Goal is to identify novel small molecule therapies to address a wide range of immune-mediated diseases.
Friday, March 14, 2014
Multimillion Pound Investment in UK Life Sciences Research and Development
UCB invests over £3 million in new bespoke cutting-edge robotic platform for UK R&D HQ.
Wednesday, December 11, 2013
UCB Receives CHMP Positive Opinion for Cimzia in Active PsA
Positive opinion is supported by data from the RAPID™-PsA study.
Monday, October 28, 2013
UCB Announces Third Research Collaboration with Harvard University
New Research Alliance project to focus on human microbiome to develop new therapeutic applications in immunology.
Wednesday, October 10, 2012
UCB to Showcase Immunology Portfolio at EULAR 2012
Data to be presented on certolizumab pegol, epratuzumab and CDP7851/AMG 785.
Thursday, July 05, 2012
Scientific News
Platelets are the Pathfinders for Leukocyte Extravasation During Inflammation
Findings from the study could help in the prevention and treatment of inflammatory pathologies.
Dengue Virus Exposure May Amplify Zika Infection
Researchers at Imperial College London have found that the previous exposure to the dengue virus may increase the potency of Zika infection.
Itchy Inflammation Of Mosquito Bites Helps Viruses Replicate
The itchy swelling that appears at the site of a mosquito bite isn't just an irritating nuisance - it also makes viral infections spread by the insects far worse, new research has found.
Guided Chemotherapy Missiles
Latching chemotherapy drugs onto proteins that seek out tumors could provide a new way of treating tumors in the brain or with limited blood supply that are hard to reach with traditional chemotherapy.
Revealing T-Cells in Action
Salk scientists show how T-cell receptors reposition during an immune response, revealing more on how the immune system is regulated.
Impact of Antibiotic Treatment on the Infant Gut Microbiome
Study shows that antibiotic treatment reduces stability and diversity of microbial population in the first three years of life.
Viruses Hack Their Host's Genome with CRISPR
A virus that infects major freshwater bacteria appears to use stolen bits of immune system DNA to highjack their hosts’ immune response.
Reclaiming The Immune System's Assault On Tumors
EPFL study shows a way to reclaim corrupted immune cells.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Blood Test That Detects Early Alzheimer’s Disease
A research team, led by Dr. Robert Nagele from Rowan University School of Osteopathic Medicine and Durin Technologies, Inc., has announced the development of a blood test that leverages the body’s immune response system to detect an early stage of Alzheimer’s disease – referred to as the mild cognitive impairment (MCI) stage – with unparalleled accuracy.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!